Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4)
Clinical and Experimental Immunology · 24.03.2023 · 211 (3) · 239-247
DOI: 10.1093/cei/uxad005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 19.01.2023. Verfasst von Abby D Ivey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Cell Biology, West Virginia University, Morgantown, WV, USA. Hauptthemen laut MEDLINE: Extracellular Traps. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Neutrophil extracellular traps (NETs) occur when chromatin is decondensed and extruded from the cell, generating a web-like structure. NETs have been implicated in the pathogenesis of several sterile disease states and thus are a potential therapeutic target. Various pathways have been shown to induce NETs, including autophagy, with several key enzymes being activated like peptidyl arginine deiminase 4 (PAD4), an enzyme responsible for citrullination of histones, allowing for DNA unwinding and subsequent release from the cell. Pre-clinical studies have already demonstrated that chloroquine (CQ) and hydroxychloroquine (HCQ) are able to reduce NETs and slow disease progression. The exact mechanism as to how these drugs reduce NETs has yet to be elucidated. CQ and HCQ decrease NET formation from various NET activators, independent of their autophagy inhibitory function. CQ and HCQ were found to inhibit PAD4 exclusively, in a dose-dependent manner, confirmed with reduced CitH3+ NETs after CQ or HCQ treatment. Circulating CitH3 levels were reduced in pancreatic cancer patients after HCQ treatment. In silico screening of PAD4 protein structure identified a likely binding site interaction at Arg639 for CQ and Trp347, Ser468, and Glu580 for HCQ. SPR analysis confirmed the binding of HCQ and CQ with PAD4 with KD values of 54.1 µM (CQ) and 88.1 µM (HCQ). This data provide evidence of direct PAD4 inhibition as a mechanism for CQ/HCQ inhibition of NETs. We propose that these drugs likely reduce NET formation through multiple mechanisms; the previously established TLR9 and autophagy inhibitory mechanism and the novel PAD4 inhibitory mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Cell Biology, West Virginia University, Morgantown, WV, USA.
- Department of Surgery, West Virginia University, Morgantown, WV, USA.
- Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.
- Department of Surgery, UT Southwestern, Dallas, TX, USA.
- Pharmaceutical Sciences, West Virginia University, Morgantown, WV, USA.
- Neuroscience, West Virginia University, Morgantown, WV, USA.
ORCID-Profile: Brian A Boone
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Ivey, A. D., Matthew Fagan, B., Murthy, P., Lotze, M. T., Zeh, H. J., Hazlehurst, L. A., Geldenhuys, W. J., & Boone, B. A. (2023). Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4). Clinical and Experimental Immunology, 211(3), 239-247. https://doi.org/10.1093/cei/uxad005
Vancouver
Ivey AD, Matthew Fagan B, Murthy P, Lotze MT, Zeh HJ, Hazlehurst LA, et al. Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4). Clinical and Experimental Immunology. 2023;211(3):239-247. doi:10.1093/cei/uxad005
BibTeX
@article{Ivey2023,
author = {Ivey, Abby D and Matthew Fagan, B and Murthy, Pranav and Lotze, Michael T and Zeh, Herbert J and Hazlehurst, Lori A and Geldenhuys, Werner J and Boone, Brian A},
title = {Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4)},
journal = {Clinical and Experimental Immunology},
year = {2023},
volume = {211},
number = {3},
pages = {239--247},
doi = {10.1093/cei/uxad005}
}
EUVIMED